Despite encouraging clinical evidence, copyright's Vyndamax, a medication for hereditary transthyretin-mediated amyloidosis (hATTR), is facing significant opposition from pharmacy benefit managers. Such organizations are often creating obstacles to coverage, like high expense criteria and PA that